Algeta appoints senior vp, Protein Therapeutics

New role created to drive development of Thorium platform

Algeta, a Norwegian company focused on the development of novel targeted cancer therapeutics, has appointed Lars Abrahmsen as senior vp, Protein Therapeutics.

Abrahmsen takes responsibility for the development of Oslo-based Algeta’s Thorium platform and for building and overseeing the preclinical development of a pipeline of alpha-pharmaceutical candidates based on tumour-targeted thorium-227 conjugates.

This builds on the progress made with Alpharadin, an alpha-pharmaceutical being developed in a phase III trial by Algeta and Bayer Schering Pharma for treating bone metastases arising from castration-resistant prostate cancer.

Abrahmsen has joined Algeta from Affibody, a Swedish company developing proprietary targeting molecules for therapeutic and diagnostic purposes, where he held the position of chief scientific officer since 2004. Prior to this he worked for Genentech and Pharmacia, where he established their phage display and antibody cloning capabilities.

You may also like

Regulatory

Anticancer agent – radium-223 chloride

Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development

Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227

Norwegian firm to create pipeline of cancer-destroying drugs
Research & Development

Algeta to collaborate with Genzyme

To evaluate Thorium-227 conjugated with a novel tumour-targeting antibody
Research & Development

Algeta signs Alpharadin manufacturing deals

Triggers €5m milestone payment from Bayer Schering Pharma
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Subscribe now